Wee Tee Hsien, CEO of FUJIFILM Business Innovation Singapore
Singapore is rapidly emerging as a global hub for AI-driven innovation, with its bioscience and biopharma sectors at the forefront of this transformation. As the nation celebrates its 60th anniversary, Singapore’s digital economy is at a pivotal crossroads, propelled by advancements in AI, the implementation of national digital programs, and the establishment of cross-border data trust frameworks. As the country develops its Smart Nation roadmap, maintaining trust, resilience, and security will be a key component of ensuring compliance in an increasingly complex digital landscape. Policymakers, stakeholders and enterprises are striving to mitigate risks by redefining cyber security strategies to align with national priorities and the changing regulatory environment.
In the bioscience and biopharma sectors, where precision, compliance, and efficiency are paramount, AI is reshaping traditional workflows and enabling breakthroughs in research, development, and manufacturing. Embracing the momentum, the global leader in innovations, FUJIFILM Business Innovation Singapore leverages advanced technologies to assist organizations in optimizing operations, improving data management, and fostering innovation through pioneering efforts and partnerships to build the country’s first legally compliant large-scale data factory. Over the next three years, to combat cybersecurity challenges in bioscience operations and unlock growth potentials, the company will build strategic partnerships and develop comprehensive digital transformation solutions that integrate AI, automation, and data intelligence.
In Singapore's increasingly AI-driven economy, Fujifilm extends stakeholder partnerships to equip SMEs with a secure enterprise-ready AI ecosystem, establishing new benchmarks for operational excellence and innovation. A robust cyber-security and artificial intelligence framework is at the heart of Singapore's commitment to advancing its digital infrastructure. Wee Tee Hsien, CEO of FUJIFILM Business Innovation Singapore, presented an overview of Singapore's strategic digital economy evolution, emphasizing the country's exciting digital economy transition.
What are the key obstacles bioscience companies encounter in adopting AI and digital transformation? What role do stakeholder partnerships play in overcoming these challenges?
Bioscience companies face a combination of data, process, regulatory, and content-management challenges that make digital and AI adoption increasingly complex.
Often, data management remains a key challenge as companies generate vast volumes of clinical and manufacturing data that are fragmented across spreadsheets and legacy systems. At the same time, compressed development timelines, manufacturing-scale variability, and manual workflows create operational bottlenecks that hinder productivity and highlight the need for automation and real-time insights. Layered on top of these pressures is a complex and evolving global regulatory environment, coupled with strict data-integrity expectations and extensive documentation requirements. Scientific and regulatory content scattered across multiple repositories further complicates collaboration, version control, and audit readiness.
These challenges are deeply interconnected: poor data governance affects regulatory compliance; fragmented content systems slow operational workflows; and manual processes hinder both efficiency and innovation.
AI, automation, and data intelligence are reshaping how businesses operate, from small and medium-sized enterprises to large corporations. As organisations navigate through digital transformation, FUJIFILM Business Innovation Singapore signed a Memorandums of Understanding (MOUs) with three strategic partners namely Trusted Hub, Bizmann System, and ReN3, to provide comprehensive digital transformation solutions, including data management, process automation, and AI-powered insights. Marking its 60th anniversary and aligning with Singapore’s SG60 celebrations, the company reinforces its commitment to empowering businesses with advanced technologies. These collaborations aim to address complex challenges to streamline operations and strategicaly drive innovation and equip organizations for success in an AI-driven economy.
How does FUJIFILM Business Innovation Singapore's 60th-anniversary focus on innovation align with the evolving demands of the bioscience and biopharma industries in Singapore and globally?
Our 60th anniversary underscores six decades of innovation and commitment to helping organisations transform digitally. Through our strategic partnerships, we aim to empower companies, including those in bioscience and biopharma, to manage data securely, optimise supply chains and finance operations, and automate content workflows.
By integrating advanced technology with industry expertise, we ensure companies are equipped to innovate sustainably, enhance operational efficiency, and thrive in evolving regulatory and market landscapes locally and globally. This aligns with our 60th anniversary tagline, “Where Work Flows, Smiles Follow,” reflecting our continued focus on delivering meaningful value to our customers.
Partnerships with Trusted Hub, Bizmann, and ReN3 provide end-to-end digital transformation solutions tailored to highly regulated sectors like bioscience and biopharma. The collaborative approach aims to address pressing challenges by digitising records into AI-ready formats. By implementing Trusted DataVerse, automating core operational workflows with Bizmann, and deploying ReN3’s AI-powered content management to streamline document handling and collaboration, the partnerships enables legally compliant, seamless data management, optimising procurement, supply chain, and finance workflows. Collectively, these solutions reduce risk, accelerate AI adoption, and allow organisations to focus on innovation and research outcomes.
By combining advanced technology with FUJIFILM Business Innovation Singapore’s expertise in workflow digitisation and managed services, these partnerships help organisations overcome fragmented data, regulatory challenges, and operational inefficiencies, driving greater business outcomes, improved collaboration, and sustainable innovation. Bizmann System’s Business Process Management (BPM) platform digitises and automates procurement, supply chain, and finance processes, facilitates executions of agentic AI workflows. This provides real-time inventory tracking, automated approvals, and improved operational control, reducing manual errors and shortening processing cycles. Users can even redesign and automate their business processes with the available zero code feature in the platform.
ReN3 delivers an agentic AI platform that automates content classification, retrieval, and workflow integration across documents, multimedia, and enterprise systems. Bioscience organisations benefit from reduced administrative workload, faster access to research and regulatory information, enhanced compliance, and improved collaboration, all while maintaining human oversight for critical decisions.
By streamlining these core processes, biopharma companies can scale efficiently, optimise resource allocation, and focus on critical R&D and production activities while maintaining compliance with regulatory standards.
Trusted DataVerse converts physical and digital records into Trusted Electronic Originals (TEOs) that are accurately preserved, legally admissible with full digital rights management and well-structured for AI use cases.
For bioscience companies, this ensures high data fidelity, regulatory compliance, secure storage, rapid retrieval, and data that is ready for training expert AI models or as LLM prompt context through Retrieval Augmented Generation (RAG). By digitising and centralising high volumes of research and clinical data, the platform reduces reliance on manual processes and physical storage, accelerates data access for studies and regulatory reporting, support autonomous AI research, and strengthens data integrity across the organisation.
Our collaberative approach ensures scalability and security by embedding compliance and governance into each solution. Trusted DataVerse provides encrypted, high fidelity, legally admissible storage with full audit trails and digital rights management, Bizmann delivers cloud-ready workflow automation capable of scaling with operations, and ReN3 offers SOC2-accredited security, role-based access control, and automated redaction.
The end-to-end service delivery, workflow integration, and ongoing operational support, allow bioscience organisations to scale securely and meet regulatory requirements without compromising efficiency or AI-readiness. These initiatives have led to a reduction in manual processing, increased operational efficiency, and strengthened compliance across various industries.
As well, we implemented an AI-powered Intelligent Document Processing (IDP) platform for healthcare organizations, enabling the automation of medical record indexing, enhancing productivity, and achieving highest data accuracy.
Automated audit trails, regulatory compliance documentation, and seamless integration with enterprise systems reduce risk and improve decision-making. The ability to operate in a private cloud or air-gapped environment provides the bioscience organisations with the data security they needed to ensure minimal data exposure risks. Coupled with Trusted DataVerse and Bizmann solutions, this results in AI-ready, structured data, streamlined procurement and supply chain operations, and improved research productivity, regulatory compliance, and decision-making capabilities.
These outcomes demonstrate measurable success in efficiency, accuracy, and compliance that translate directly to the bioscience sector, where timely access to data and regulatory adherence are critical for research and clinical operations.
